A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Johnson & Johnson (J&J)

Status and phase: Completed; Phase 3

Conditions: Low Back Pain

Treatments: Drug: oxycodone CR; Drug: placebo; Drug: tapentadol (CG5503) ER

Study type: Interventional

Funder types: Industry

Identifiers

NCT00449176

CR013399

R331333PAI3011 (Other Identifier)

Details and patient eligibility

About

The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain of the lower back, in comparison with placebo and Oxycodone Controlled Release (CR).

Full description

The primary objective of this randomized (study medication assigned to patients by chance), double-blind (neither patient nor investigator knows the study medication), phase III, placebo and active controlled trial is to evaluate the efficacy and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses 100-250 mg twice daily in patients with moderate to severe chronic pain of the lower back. The study is being conducted for registration and approval of tapentadol (CG5503) in the US and outside US. The trial will consist of five periods: screening (to assess eligibility), washout (3-7 days with determination of baseline pain intensity), titration (of dose over 3 weeks to the optimal individual level), maintenance (investigational drug intake for 12 weeks with adjustments allowed), and follow-up (2 weeks post treatment discontinuation). The study hypothesis is that the study drug will be more effective than placebo in reducing patients' pain intensity. The Secondary objectives include the collection of pharmacokinetic (related to how the body uses the drug) information for dose verification. The trial objectives will be assessed by comparing the baseline pain level to the level of week 12 of the maintenance phase. This will be done by looking at the patient's pain diary information. Titrate tapentadol (CG5503) ER (extended release) in 50 mg steps to patient's optimal dose ranging between 100mg and 250mg twice a day; Oxycodone CR (controlled release) 20mg to 50mg twice a day; Placebo (no active ingredients). All doses of trial treatment will be taken orally with or without food, for a maximum timeframe of 15 weeks.

Enrollment: 981 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and non-pregnant, non-lactating women having a diagnosis of Lower Back Pain (LBP) of non-malignant origin present for at least 3 months
• Patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy
• Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to < 160 mg of oral morphine
• Baseline score of =5 on an 11-point numerical rater scale, calculated as the average pain intensity during the last 3 days prior to randomization.

Exclusion criteria

• History of alcohol and/or drug abuse in Investigator's judgement
• History of significant liver insufficiency
• chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months
• Life-long history of seizure disorder or epilepsy
• History of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated
• Uncontrolled hypertension
• Patients with severely impaired renal function
• Patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

981 participants in 3 patient groups, including a placebo group

001

Experimental group

Description:

tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks

Treatment:

Drug: tapentadol (CG5503) ER

002

Active Comparator group

Description:

oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks

Treatment:

Drug: oxycodone CR

003

Placebo Comparator group

Description:

placebo matching placebo twice daily for 15 weeks

Treatment:

Drug: placebo